Macroscopic appearance of Type IV and giant Type III is a high risk for a poor prognosis in pathological stage II/III advanced gastric cancer with postoperative adjuvant chemotherapy

Table 4 Initial recurrent sites and RTKs expression in high risk gastric cancer with relapse

Case	Age	Sex	13th JGCA pT	13th JGCA pN	13th JGCA pStage	Macroscopic features	EGFR	HER2	HER3	IGF1R	EphA2	Initial recurrences
1	74	M	3	2	IIIB	Giant type III	2+	1+	2+	2+	1+	#16 LN
2	62	M	3	2	IIIB	Giant type III	2+	0+	1+	2+	0+	#20 LN
3	79	F	3	2	IIIB	Giant type III	2+	1+	1+	0+	1+	#13 LN
4	68	M	3	2	IIIB	Giant type III	3+	1+	1+	1+	0+	#16,13
5	68	M	3	2	IIIB	Giant type III	3+	0+	1+	1+	1+	#13 LN
6	45	M	3	2	IIIB	Giant type III	2+	3+	2+	0+	2+	#13 LN
7	69	M	3	2	IIIB	Giant type III	3+	3+	1+	1+	2+	liver
8	71	M	3	1	IIIA	Type IV	2+	0+	1+	1+	0+	#13 LN
9	69	F	3	1	IIIA	Type IV	2+	0+	2+	1+	0+	Peritoneum
10	69	M	3	1	IIIA	Type IV	1+	2+	0+	1+	1+	Peritoneum
11	59	F	3	2	IIIB	Type IV	1+	1+	1+	1+	0+	Peritoneum

JGCA: Japanese Gastric Cancer Association; M: Male; F: Female; EGFR: Epidermal growth factor receptor; HER2: Human epidermalgrowth factor receptor-2; IGF1R: Insulin-like growth factor 1.